drugset / Trial / NCT04546022
GSP as an Novel Indicator for Residual Liver Function in Patients With Fatty Liver
Phase 1/2
Completed
210 enrolled
National Defense Medical Center, Taiwan
Cardinal Tien Hospital · collabTri-Service General Hospital (TSGH) · collab
NaSingle-groupOpen-labelScreening
Summary
The primary objective is to determine the galactose single point (GSP) cutoff values to discriminate subjects with different hepatic function. The secondary objective is to analyze the correlations between GSP and other hepatic function assessment methods among this trial subjects.
Timeline
- Start
- 2007-07-05
- Primary completion
- 2007-08-12
- Completion
- 2018-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Galactose | Diagnostic / imaging agent | 400 mg/ml | Intravenous |
Indications
No indication recorded.